{"schema_version":"secwatch.filing_event.v1","accession":"0001388658-23-000006","form_type":"8-K","ticker":"IRTC","cik":"0001388658","company_name":"iRhythm Holdings, Inc.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.717580+00:00","generated_at":"2026-06-19T02:18:03.899734+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"iRhythm Q4 revenue $112.6M (+37.7% YoY); adjusted EBITDA positive $1.1M; guides 2023 rev $475-485M","bullets":["Q4 revenue $112.6M (+37.7% YoY); gross margin 69.9% (up 720 bps); net loss $20.2M ($0.67 loss per share) vs $32.5M loss in Q4 2021.","Q4 adjusted EBITDA $1.1M, first positive quarter; full year adjusted EBITDA -$11.3M, improvement of $24.4M YoY.","Full year 2022 revenue $410.9M (+27.3% YoY); net loss $116.2M ($3.88 loss per share) vs $101.4M loss in 2021.","2023 guidance: revenue $475-485M (16-18% growth); gross margin 69-70%; adjusted EBITDA margin -0.5% to 0.5%.","Operational: CMS Final Rule with national CPT rates; FDA clearance for ZEUS system update; health economic data presented at AHA."],"urls":{"canonical":"https://secwatch.observer/filing/0001388658-23-000006","json":"https://secwatch.observer/filing/0001388658-23-000006.json","markdown":"https://secwatch.observer/filing/0001388658-23-000006.md","text":"https://secwatch.observer/filing/0001388658-23-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388658/000138865823000006/0001388658-23-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388658/000138865823000006/irtc-20230223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T02:18:03.899734+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"262b57588b2475ac734b2c82ef6225764697e002","claim":"iRhythm Holdings, Inc. updated its the fourth quarter and full year ended December 31, 2022 guidance (initiated).","evidence_excerpt":"On February 23, 2023, iRhythm Technologies, Inc. issued a press release regarding its financial results for the fourth quarter and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1388658/000138865823000006/0001388658-23-000006-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a2aac6857b539bfbbc30c9ad8a436131292ccec3","claim":"iRhythm Holdings, Inc. reported year ended December 31, 2022 results: revenue $410.9 million, net income $116.2 million, EPS $3.88 per share. Guidance initiated.","evidence_excerpt":"equivalents and short-term investments of $213.1 million at December 31, 2022, a $9.6 million increase from September 30, 2022 Full Year 2022 Financial Highlights • Revenue of $410.9 million, a 27.3% increase compared to full year 2021 • Gross margin of 68.5%, a 238 basis point increase compared to full year 2021 • Net loss of $116.2 million, reflecting an increase","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1388658/000138865823000006/0001388658-23-000006-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2022"},{"label":"Revenue","value":"$410.9 million"},{"label":"Net income","value":"$116.2 million"},{"label":"EPS","value":"$3.88 per share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"cec53989f4fea528f004ac5f65b5cd081a02b372","claim":"iRhythm Holdings, Inc. reported the three months and full year ended December 31, 2022 results: revenue $112.6 million, net income $20.2 million, EPS $0.67 per share. Guidance initiated.","evidence_excerpt":"predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 2022. Fourth Quarter 2022 Financial Highlights • Revenue of $112.6 million, a 37.7% increase compared to fourth quarter 2021 • Gross margin of 69.9%, a 720 basis point improvement compared to fourth quarter 2021 • Net loss of $20.2 million, a $12.3","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1388658/000138865823000006/0001388658-23-000006-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months and full year ended December 31, 2022"},{"label":"Revenue","value":"$112.6 million"},{"label":"Net income","value":"$20.2 million"},{"label":"EPS","value":"$0.67 per share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}